• Users Online: 458
  • Print this page
  • Email this page
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2011| January-March  | Volume 5 | Issue 1  
    Online since December 4, 2017

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
XXI Annual conference of indian society of organ transplantation (isot), hyderabad 21st - 23rd october, 2010

January-March 2011, 5(1):9-45
  844 40 -
HLA Antibody incompatible transplantation – a mini review
Nithya S Krishnan, Daniel Zehnder, David Briggs, Robert Higgins
January-March 2011, 5(1):1-5
Antibody incompatible transplantation (AiT) is on the rise. This is because of advances in detection of donor specific antibodies, even at very low levels. In spite of this there is an increased risk of acute antibody mediated rejection. There are multiple protocols to prevent and treat antibody mediated rejection. Though they are reasonably successful in reversing acute rejection, graft loss still occurs due to ongoing chronic antibody mediated rejection.
[ABSTRACT]   Full text not available  [PDF]  [Mobile Full text]  [EPub]
  247 35 -
C5b-9 inhibitor (eculizumab) for antibody-mediated rejection in renal transplantation
Rizwan Hamer, Nithya Krishnan, David Lowe, David Briggs, Daniel Zehnder, Robert Higgins
January-March 2011, 5(1):6-8
Increasingly successful protocols enabling HLA antibody incompatible renal transplantation have resulted in a rise in the incidence of antibody mediated rejection. There are limited options to treat this feared complication. Eculizumab, a potent inhibitor of the complement cascade, has recently been suggested as a possible addition to treatment of AMR. We report the use of eculizumab in three very high risk transplant recipients.
[ABSTRACT]   Full text not available  [PDF]  [Mobile Full text]  [EPub]
  254 15 -